Matt has over 25 years of experience in technical and commercial leadership roles driving rapid growth for companies enabling the biotech industry with innovative bioprocess manufacturing solutions. After beginning his career at the MIT Center for Genome Research working on the Human Genome Project, Matt focused on driving the industry adoption of disruptive technologies at a variety of organizations including Millipore, Stedim, ATMI, and through acquisition, Sartorius, GE (now Cytiva), and Pall Corporation. Prior to joining Andelyn, Matt was a leader in Pall’s Integrated Solutions program where his team provided end-to-end manufacturing solutions and platforms, driving efficiency in the scale-up and manufacturing of gene therapy, protein therapeutic, and vaccine processes. Matt joined Andelyn in March 2023 as Chief Commercial Officer to take the company through its next phase of substantial growth in the clinical and commercial manufacturing of gene therapies. He holds Bachelor and Master of Science degrees in Biology from McGill University in Montreal, Canada.